Kenneth J Cohen


If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where Kenneth J Cohen is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 10 Similar Profiles
Pediatrics Medicine & Life Sciences
Glioma Medicine & Life Sciences
Astrocytoma Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Brain Neoplasms Medicine & Life Sciences
Medulloblastoma Medicine & Life Sciences
Radiotherapy Medicine & Life Sciences
temozolomide Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1994 2019

A phase I and pharmacokinetic study of oral dabrafenib in children and adolescent patients with recurrent or refractory BRAF V600 mutation–positive solid tumors

Kieran, M. W., Geoerger, B., Dunkel, I. J., Broniscer, A., Hargrave, D., Hingorani, P., Aerts, I., Bertozzi, A. I., Cohen, K. J., Hummel, T. R., Shen, V., Bouffet, E., Pratilas, C. A., Pearson, A. D. J., Tseng, L., Nebot, N., Green, S., Russo, M. W. & Whitlock, J. A., Dec 15 2019, In : Clinical Cancer Research. 25, 24, p. 7294-7302 9 p.

Research output: Contribution to journalArticle


Efficacy and safety of dabrafenib in pediatric patients with BRAF V600 mutation–positive relapsed or refractory low-grade glioma: Results from a phase I/IIa study

Hargrave, D. R., Bouffet, E., Tabori, U., Broniscer, A., Cohen, K. J., Hansford, J. R., Geoerger, B., Hingorani, P., Dunkel, I. J., Russo, M. W., Tseng, L., Dasgupta, K., Gasal, E., Whitlock, J. A. & Kieran, M. W., Dec 15 2019, In : Clinical Cancer Research. 25, 24, p. 7303-7311 9 p.

Research output: Contribution to journalArticle

Confidence Intervals

Accelerating Pediatric Cancer Drug Development: Challenges and Opportunities for Pediatric Master Protocols

Khan, T., Stewart, M., Blackman, S., Rousseau, R., Donoghue, M., Cohen, K. J., Seibel, N., Fleury, M., Benettaib, B., Malik, R., Vassal, G. & Reaman, G., Jan 1 2018, (Accepted/In press) In : Therapeutic Innovation and Regulatory Science.

Research output: Contribution to journalArticle

Pharmaceutical Preparations
Clinical Trials
Drug Approval

A phase 1/2 dose-finding, safety, and activity study of cabazitaxel in pediatric patients with refractory solid tumors including tumors of the central nervous system

Manley, P. E., Trippett, T., Smith, A. A., Macy, M. E., Leary, S. E. S., Boklan, J., Cohen, K. J., Goldman, S., Kilburn, L. B., Dhall, G., Devin, J., Herzog, C. E., Partap, S., Fauchet, F., Badreddine, E., Bernard, J. P. & Chi, S. N., Sep 1 2018, In : Pediatric Blood and Cancer. 65, 9, e27217.

Research output: Contribution to journalArticle

Central Nervous System Neoplasms
Maximum Tolerated Dose
Cranial Irradiation
Corpus Callosum
Prospective Studies